Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access

While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Melissa Cotrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sat down with Editor in Chief Matthew Hadfield, DO, Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, to unpack the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies. Together, they explore how the oncology community can translate trial availability into meaningful access. 

Shifting Mindsets: Clinical Trials as a Frontline Option

Historically viewed as salvage strategies after standard approaches had failed, clinical trials have evolved rapidly over the past decade. Dr. Hadfield explained that "the landscape of drug development has changed so much and so quickly over the last 10 to 15 years that trials now represent the most promising therapies that are available, particularly in patients who have not responded the way we would've hoped with standard-of-care therapies." 

In fact, in certain disease settings with limited effective standard regimens, early- and late-phase studies are increasingly considered earlier in treatment algorithms. Dr. Hadfield emphasized that "the general thinking of oncology now is that every patient should have access to a clinical trial if they have cancer."

Dismantling Common Patient Misconceptions 

Despite clinical promise, patient hesitancy and fear often stand in the way of enrollment. According to Dr. Hadfield, "far and away, the most common misconception that I am asked about is whether or not someone would be getting a placebo." He clarified that oncology studies are designed to ensure that active therapy is delivered, noting that "there are no placebo-only trials. They're open-label, meaning that the investigator, the patient, and the company all know the treatment that the patient is getting." Placebos are used only in randomized phase 3 trials when added directly to an approved standard-of-care backbone.

Addressing anxieties surrounding being treated like a test subject, Dr. Hadfield noted that "the reality is that clinical trials, especially in oncology, are the pathway to the most promising therapies that we have available," developed from extensive laboratory and translational science aimed entirely at patient benefit.

Balancing Trial Safety With Real-World Eligibility

Strict protocol eligibility criteria remain a major barrier, frequently excluding individuals with organ dysfunction, baseline laboratory abnormalities, or common comorbidities. Trialists face an ongoing challenge as they navigate "trying to find a balance between ensuring that patients are safe in the study and don't have comorbidities that make them more predisposed to developing toxicities that could be severe or life-threatening, but also ensuring that a trial is applicable to a real-world population where patients will have comorbidities and get these drugs if they are proven to be efficacious and approved from a regulatory standpoint."

When considering potential systemwide reforms, Dr. Hadfield advocated for more tailored requirements, stating that "the eligibility criteria should be very specific for each drug that's being studied. For instance, if a drug doesn't have any real rationale for causing anemia, there really shouldn't be a strict cutoff for hemoglobin."

Navigating "Life Eligibility" and Building Relationships

Beyond clinical parameters, the logistical demands of trial participation, often termed "life eligibility,” can derail enrollment, particularly for patients from disadvantaged socioeconomic backgrounds or rural areas. Intensive schedules with frequent blood draws for pharmacokinetic sampling, monitoring visits, and travel create heavy burdens. Dr. Hadfield pointed out that "those conversations, I find, are better if they're iterative," giving patients and families the necessary time and space to process information and expectations.

Overcoming these access hurdles also depends heavily on collaboration between local clinicians and academic centers. Dr. Hadfield emphasized that "honestly, I think the most important thing is building relationships," ensuring that community providers feel fully supported to reach out directly to trial investigators whenever a patient might benefit from an investigational protocol.

Conclusion

Closing the oncology clinical trial access gap requires intentional collaboration among investigators, regulatory bodies, and community clinicians. By modernizing rigid eligibility criteria, addressing the real-world logistical burdens of intensive study visits, transparently addressing patient fears about placebos, and maintaining open referral channels, the oncology community can dismantle longstanding barriers and make cutting-edge trial participation feasible for all patients.

Key Takeaways

• Clinical trials have transitioned from being viewed strictly as last-resort options to representing the most promising therapeutic avenues and, in select tumor types, preferred frontline strategies.

• Clinicians must actively dispel misconceptions about placebos, emphasizing that oncology trials provide open-label investigational agents or add novel drugs to proven standard-of-care backbones.

• Overly rigid eligibility criteria restrict access and yield study populations that do not reflect real-world oncology practice, underscoring the need for drug-specific, rationalized inclusion rules.

• Logistical and time demands—such as frequent clinic visits and pharmacokinetic testing—pose significant hurdles that require empathetic, iterative patient counseling to navigate effectively.

• Strong, reciprocal relationships between community practices and academic cancer centers remain the most critical catalyst for expanding clinical trial identification and enrollment.